Shaping the future of animal health
Virbac group

Corporate news

Jun 23 - Virbac group: Sébastien Huron will become the new chairman of the executive board as of December 2017

Virbac has announced the supervisory board’s intention to appoint Sébastien Huron as chairman of Virbac’s executive board, as of next December, when the mandate of the current chairman of the executive board, Éric Marée, expires. 

Jun 16 - Virbac signs a research agreement with Bio-Gene

Bio-Gene announces collaboration agreement with Virbac for development of FLAVOCIDE™ as an insect control agent in ruminants. 

May 31 - Effipro® Duo: treat and prevent flea and tick infestations

In May 2016, European practitioners (France, UK and Austria) discovered Effipro® Duo, a new parasiticide used to treat and prevent tick and flea infestations in dogs and cats. The advantages of this product described by the Global Marketing manager parasiticides.

A company that has always been dedicated to animal health

Founded in 1968 by a French veterinarian, Virbac is an independent pharmaceutical laboratory present in more than 100 countries. The company offers a comprehensive and practical range of products and services covering the majority of species and pathologies.

Join Virbac

Career opportunities, company values, testimonials... Discover our career section.

Customer driven innovation

To meet the customers' essential needs, in almost all the therapeutic segments and for nearly all species. Such is the philosophy of Virbac innovation. For this purpose, the company develops...

Financial public releases

Apr 12 - 2017 first quarter consolidated sales

  First quarter 2017 sales down, strongly impacted by stock effects in the distribution in the United States

Mar 13 - 2016 annual results

  Strong rebound in profitability in 2016  

Jan 17 - 2016 Annual consolidated sales

  Annual sales growth of 4.5%, at constant exchange rates

Corporate responsibility

Company culture, economic and social responsibility, citizenship, environment... From its very beginning, close to fifty years ago, Virbac has taken a long-term view.